Aggressive lymphoma: improving treatment outcome with rituximab.

@article{Coiffier2002AggressiveLI,
  title={Aggressive lymphoma: improving treatment outcome with rituximab.},
  author={Bertrand Coiffier and Michael Pfreundschuh and Rolf Arno Stahel and Julie Marie Vose and Pier Luigi Zinzani},
  journal={Anti-cancer drugs},
  year={2002},
  volume={13 Suppl 2},
  pages={
          S43-50
        }
}
The standard therapy for patients with aggressive lymphoma is cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy, which achieves a complete response in more than 60% of patients but is curative in only about 40-50%. More aggressive and/or dose-intensified chemotherapy regimens have failed to provide significant survival advantages compared with CHOP, and may have higher toxicity. Rituximab, a chimeric monoclonal antibody to the CD20 antigen, is effective as… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 10 CITATIONS

Similar Papers

Loading similar papers…